BR112017004949A2 - receptor do antígeno quimérico, polinucleotídeo, vetor, célula, e, composição farmacêutica. - Google Patents
receptor do antígeno quimérico, polinucleotídeo, vetor, célula, e, composição farmacêutica.Info
- Publication number
- BR112017004949A2 BR112017004949A2 BR112017004949A BR112017004949A BR112017004949A2 BR 112017004949 A2 BR112017004949 A2 BR 112017004949A2 BR 112017004949 A BR112017004949 A BR 112017004949A BR 112017004949 A BR112017004949 A BR 112017004949A BR 112017004949 A2 BR112017004949 A2 BR 112017004949A2
- Authority
- BR
- Brazil
- Prior art keywords
- chimeric antigen
- polynucleotide
- vector
- cell
- pharmaceutical composition
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- -1 cell Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 230000007514 neuronal growth Effects 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001128—CD44 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464428—CD44 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biotechnology (AREA)
Abstract
um receptor do antígeno quimérico (car) compreendendo um espaçador extracelular que compreende pelo menos parte do domínio extracelular do fator de crescimento neural de baixa afinidade humano (lngfr) ou um derivado do mesmo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14184838 | 2014-09-15 | ||
PCT/IB2015/057049 WO2016042461A1 (en) | 2014-09-15 | 2015-09-14 | Chimeric antigen receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017004949A2 true BR112017004949A2 (pt) | 2017-12-05 |
Family
ID=51541003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017004949A BR112017004949A2 (pt) | 2014-09-15 | 2015-09-14 | receptor do antígeno quimérico, polinucleotídeo, vetor, célula, e, composição farmacêutica. |
Country Status (23)
Country | Link |
---|---|
US (1) | US11299529B2 (pt) |
EP (3) | EP3575315B1 (pt) |
JP (1) | JP6684782B2 (pt) |
KR (1) | KR20170054505A (pt) |
CN (1) | CN107074930A (pt) |
AU (1) | AU2015316480B2 (pt) |
BR (1) | BR112017004949A2 (pt) |
CA (1) | CA2958807C (pt) |
CY (1) | CY1122607T1 (pt) |
DK (2) | DK3194434T3 (pt) |
ES (2) | ES2742528T3 (pt) |
HR (1) | HRP20191468T1 (pt) |
IL (1) | IL251030B (pt) |
LT (1) | LT3194434T (pt) |
MX (1) | MX2017003421A (pt) |
PL (1) | PL3194434T3 (pt) |
PT (2) | PT3194434T (pt) |
RU (1) | RU2745705C2 (pt) |
SG (1) | SG11201701309SA (pt) |
SI (1) | SI3194434T1 (pt) |
UA (1) | UA123764C2 (pt) |
WO (1) | WO2016042461A1 (pt) |
ZA (1) | ZA201701344B (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
JP6694875B2 (ja) | 2014-05-15 | 2020-05-20 | ナショナル ユニヴァーシティ オブ シンガポール | 改変ナチュラルキラー細胞及びその使用 |
EP3293199B1 (en) | 2016-09-08 | 2021-01-13 | Heinrich-Heine-Universität Düsseldorf | Chimeric antigen receptors |
WO2018089829A1 (en) * | 2016-11-10 | 2018-05-17 | Fortis Therapeutics, Inc. | Cd46-specific effector cells and uses thereof |
KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
JP7270253B2 (ja) | 2017-03-27 | 2023-05-10 | ナショナル ユニヴァーシティ オブ シンガポール | ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株 |
SG10201913656TA (en) | 2017-04-26 | 2020-03-30 | Eureka Therapeutics Inc | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
CN111511391A (zh) | 2017-10-18 | 2020-08-07 | 英特拉克森公司 | 包含间隔区的多肽组合物 |
WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
CN109971717B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途 |
WO2019134866A1 (en) | 2018-01-03 | 2019-07-11 | Molmed Spa | Chimeric antigen receptors containing optimal spacer region |
CN109321530B (zh) * | 2018-02-12 | 2021-03-12 | 华东师范大学 | 一种安全型嵌合抗原受体t细胞及其用途 |
EP3762012A1 (en) | 2018-03-09 | 2021-01-13 | Ospedale San Raffaele S.r.l. | Il-1 antagonist and toxicity induced by cell therapy |
US20220064599A1 (en) | 2018-05-30 | 2022-03-03 | Glycostem Therapeutics B.V. | Car nk cells |
CN110760005A (zh) * | 2018-07-25 | 2020-02-07 | 上海细胞治疗集团有限公司 | 一种靶向Glypican-3抗原的嵌合抗原受体修饰T细胞及其用途 |
CN113474362B (zh) * | 2019-01-28 | 2023-04-18 | 普众发现医药科技(上海)有限公司 | 对cd44特异性的抗体 |
AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
AU2020319094A1 (en) * | 2019-07-24 | 2022-02-03 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and chimeric stimulating receptors and uses thereof |
CA3188728A1 (en) | 2020-08-07 | 2022-02-10 | Marc Nasoff | Immunoconjugates targeting cd46 and methods of use thereof |
CN116600820A (zh) * | 2020-12-16 | 2023-08-15 | 奥赖恩公司 | 嵌合抗原受体(car)间隔子修饰增强car t细胞功能 |
AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
CN114891110A (zh) * | 2020-12-31 | 2022-08-12 | 中元汇吉生物技术股份有限公司 | 特异性结合人IgG4的蛋白及其应用 |
CN112851794B (zh) * | 2021-02-04 | 2023-05-23 | 苏州铂维生物科技有限公司 | 一种基于cd271的抗原表位及其应用 |
CN117580863A (zh) * | 2021-09-01 | 2024-02-20 | 中国科学院生物物理研究所 | 嵌合抗原受体及其用途 |
CN114133457B (zh) * | 2021-12-08 | 2022-08-19 | 郑州源创吉因实业有限公司 | 一种靶向ror1和cd33的双特异性嵌合抗原受体(car)及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
GB0221778D0 (en) | 2002-09-19 | 2002-10-30 | Molmed Spa | Conjugate |
GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Fc融合蛋白及其用途 |
GB201206559D0 (en) * | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
CN103145849B (zh) | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
CA2904369A1 (en) * | 2013-03-07 | 2014-09-12 | Baylor College Of Medicine | Targeting cd138 in cancer |
ES2791598T3 (es) * | 2013-06-05 | 2020-11-05 | Bellicum Pharmaceuticals Inc | Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa |
ES2778651T3 (es) | 2015-10-09 | 2020-08-11 | Miltenyi Biotec Technology Inc | Receptores de antígeno quimérico y métodos de uso |
-
2015
- 2015-09-14 PT PT15775814T patent/PT3194434T/pt unknown
- 2015-09-14 EP EP19181017.5A patent/EP3575315B1/en active Active
- 2015-09-14 ES ES15775814T patent/ES2742528T3/es active Active
- 2015-09-14 RU RU2017112882A patent/RU2745705C2/ru active
- 2015-09-14 US US15/511,026 patent/US11299529B2/en active Active
- 2015-09-14 CN CN201580059769.3A patent/CN107074930A/zh active Pending
- 2015-09-14 BR BR112017004949A patent/BR112017004949A2/pt not_active Application Discontinuation
- 2015-09-14 DK DK15775814.5T patent/DK3194434T3/da active
- 2015-09-14 AU AU2015316480A patent/AU2015316480B2/en active Active
- 2015-09-14 KR KR1020177010132A patent/KR20170054505A/ko active IP Right Grant
- 2015-09-14 CA CA2958807A patent/CA2958807C/en active Active
- 2015-09-14 LT LTEP15775814.5T patent/LT3194434T/lt unknown
- 2015-09-14 PL PL15775814T patent/PL3194434T3/pl unknown
- 2015-09-14 MX MX2017003421A patent/MX2017003421A/es unknown
- 2015-09-14 DK DK19181017.5T patent/DK3575315T3/da active
- 2015-09-14 WO PCT/IB2015/057049 patent/WO2016042461A1/en active Application Filing
- 2015-09-14 ES ES19181017T patent/ES2933352T3/es active Active
- 2015-09-14 EP EP22194958.9A patent/EP4159752A1/en active Pending
- 2015-09-14 JP JP2017514352A patent/JP6684782B2/ja active Active
- 2015-09-14 UA UAA201703663A patent/UA123764C2/uk unknown
- 2015-09-14 SI SI201530863T patent/SI3194434T1/sl unknown
- 2015-09-14 PT PT191810175T patent/PT3575315T/pt unknown
- 2015-09-14 SG SG11201701309SA patent/SG11201701309SA/en unknown
- 2015-09-14 EP EP15775814.5A patent/EP3194434B1/en active Active
-
2017
- 2017-02-22 ZA ZA2017/01344A patent/ZA201701344B/en unknown
- 2017-03-08 IL IL251030A patent/IL251030B/en unknown
-
2019
- 2019-08-14 HR HRP20191468 patent/HRP20191468T1/hr unknown
- 2019-08-21 CY CY20191100894T patent/CY1122607T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017004949A2 (pt) | receptor do antígeno quimérico, polinucleotídeo, vetor, célula, e, composição farmacêutica. | |
MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
BR112016024780A2 (pt) | composições e métodos relacionados com construtos de fc manipulados | |
EP3309177A4 (en) | Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof | |
CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
MY191581A (en) | Anti-pd-1 antibodies | |
MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
SG10201909716RA (en) | Modified j-chain | |
MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
MY188940A (en) | Anti-pd-l1 antibodies and diagnostic uses thereof | |
WO2016100985A3 (en) | Chimeric antigen receptors and methods of use thereof | |
EA201991006A1 (ru) | Полимерные системы для дисперсии частиц | |
MX2015017331A (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
BR112017005381A2 (pt) | composições que compreendem células recombinantes de bacillus e um inseticida. | |
WO2018081648A8 (en) | ANTI-MIC ANTIBODIES AND METHODS OF USE | |
EP3604535A3 (en) | Methods and compositions for weed control | |
SG10201808259TA (en) | Anti-jagged1 antibodies and methods of use | |
BR112018010381A2 (pt) | composições para tratamento de cabelo, condicionadora de cabelo e para alteração da cor do cabelo, sistema para tratamento de cabelo, métodos para tratamento de cabelo e para alteração da cor do cabelo, e, kit de multicompartimentos. | |
EP3259577A4 (en) | Systems, devices, and methods for detecting fertility and gender of unhatched eggs | |
BR112017005504A2 (pt) | composições que compreendem células recombinantes de bacillus e um inseticida. | |
CL2019001329A1 (es) | Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso. | |
WO2016069142A3 (en) | Contractile function measuring devices, systems, and methods of use thereof | |
MX2016004853A (es) | Metodos de uso de anticuerpos anti-ly6e. | |
BR112019008225A2 (pt) | spray de aerossol contendo espécies de bactérias viáveis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |